Treatment strategies for different types of lymphoma vary. Patients with Hodgkin’s lymphoma are potentially curable, and treatment consists of chemotherapy, radiation therapy, and autologous stem cell transplantation. Patients with stage I lymphoma without group B symptoms and without a large mass usually need to complete two courses of chemotherapy combined with local radiation therapy or four courses of chemotherapy if the treatment process is successful; the rest of the patients usually need to complete six to eight courses of chemotherapy, including radiation therapy to the affected area for patients with a large mass. Treatment of non-Hodgkin’s lymphoma is relatively complex. Since non-Hodgkin’s lymphoma is a systemic disease, treatment is based on chemotherapy, which can be supplemented with local radiotherapy for patients with residual chemotherapy masses, large local masses or central nervous system involvement. Surgical treatment is limited to a few cases such as hypersplenism and gastrointestinal non-Hodgkin’s lymphoma. In addition, biological therapy has developed rapidly in recent years. Biological therapy includes cytokines, monoclonal antibodies, etc. When biological therapy is combined with chemotherapy, the efficacy can be significantly improved. Inert lymphoma, because the tumor itself grows slowly and there is no practical and effective cure, early intervention of the disease will not bring significant benefits to patients, so in the early stage of the disease, regular follow-up is usually performed to observe changes in the disease, such as chronic lymphocytic leukemia/small lymphocytic lymphoma, which is treated only when the indications for treatment are met. The remaining more specific lymphomas, such as MALT lymphoma of the stomach, are usually associated with H. pylori infection, and antibiotic therapy to clear H. pylori can result in complete remission in more than 50% of patients. For better long-term outcomes, autologous stem cell transplantation or allogeneic transplantation after high-dose combination chemotherapy can be considered for patients under 60 years of age with aggressive lymphoma who are in good general condition but have short remission, refractory, or relapsed.